Margot Lazow
Nationwide Children's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Margot Lazow as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05843253 · Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital · recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma · study chair
- N/ANCT05839379 · Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital · recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma · study director
- Ph1/Ph2NCT05278208 · Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsNationwide Children's Hospital · recruiting · High Grade Glioma, Meningioma, Embryonal Tumor · principal investigator
- Ph1NCT03605550 · A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade GliomaNationwide Children's Hospital · active not recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase II, Multi-arm, Molecularly-Guided Umbrella Trial for Children and Young Adults with High-Grade GliomaR01FD008167 · FDA · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · fiscal years 2025 · $3,218,733 awarded in 2025Same name and institution; not confirmed by an ID
- Phase I/II Study of 177Lu-DOTATATE in Children and Young Adults with Recurrent/Progressive High-Grade CNS Tumors and Meningiomas which Express Somatostatin Type 2A Receptors [9/24/21 IND]R01FD007532 · FDA · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · fiscal years 2022 to 2024 · $485,894 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in medulloblastoma.